Early reduction of SARS-CoV-2-replication in bronchial epithelium by kinin B2 receptor antagonism

• Published in: Journal of molecular medicine (Berlin, Germany) Vol. 100; no. 4; pp. 613 - 627
• Main Authors: Jakwerth, Constanze A., Feuerherd, Martin, Guerth, Ferdinand M., Oelsner, Madlen, Schellhammer, Linda, Giglberger, Johanna, Pechtold, Lisa, Jerin, Claudia, Kugler, Luisa, Mogler, Carolin, Haller, Bernhard, Erb, Anna, Wollenberg, Barbara, Spinner, Christoph D., Buch, Thorsten, Protzer, Ulrike, Schmidt-Weber, Carsten B., Zissler, Ulrich M., Chaker, Adam M.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.04.2022; Springer Nature B.V
• Subjects: ACE2; Angiotensin-converting enzyme 2; Antagonists; Biomedical and Life Sciences; Biomedicine; COVID-19; Cytotoxicity; Epithelial cells; Epithelium; Human Genetics; Immunoregulation; Infections; Inflammation; Internal Medicine; Kallikrein; Molecular Medicine; Mucosa; Original; Original Article; Replication; Respiratory tract; Respiratory tract diseases; Severe acute respiratory syndrome coronavirus 2; Signal transduction; Transcriptomes; COVID-19; Kinin-kallikrein-system; ACE2; B; SARS-CoV-2; R-antagonist; Kinin

SARS-CoV-2 has evolved to enter the host via the ACE2 receptor which is part of the kinin-kallikrein pathway. This complex pathway is only poorly understood in context of immune regulation but critical to control infection. This study examines SARS-CoV-2-infection and epithelial mechanisms of the ki...